(Q43521896)

English

High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

Cindy Neuzillet

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Valérie Paradis

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Louis de Mestier

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jean-Baptiste Bachet

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2

object named as

Anne Couvelard

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Philippe Ruszniewski

10

object named as

Philippe Ruszniewski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

11

object named as

Eric Raymond

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Annemilaï Tijeras-Raballand

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Armand de Gramont

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

12 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

67

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

664-676

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

EMT and dissemination precede pancreatic tumor formation

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

The role of stroma in pancreatic cancer: diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Stromal biology and therapy in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

The role of pancreatic stellate cells in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

MET signalling: principles and functions in development, organ regeneration and cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Hepatocyte growth factor stimulates cell growth and enhances the expression of transforming growth factor alpha mRNA in AsPC-1 human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Development and characterization of gemcitabine-resistant pancreatic tumor cells.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

MET: a promising anticancer therapeutic target

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

REporting recommendations for tumour MARKer prognostic studies (REMARK)

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

The Measurement of Observer Agreement for Categorical Data

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Analysis of pancreatic cancer microenvironment: role of macrophage infiltrates and growth factors expression

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Microenvironment elements involved in the development of pancreatic cancer tumor.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12691

21 January 2018

Identifiers

10.1111/HIS.12691

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25809563%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43521896&oldid=2098073258"